258 related articles for article (PubMed ID: 34332098)
1. Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization.
Wang K; Chen Q; Liu N; Zhang J; Pan X
Drug Discov Today; 2021 Nov; 26(11):2743-2753. PubMed ID: 34332098
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J; Mortezaee K
Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
[TBL] [Abstract][Full Text] [Related]
3. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
4. Vascular normalization: a real benefit?
Ribatti D
Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
[TBL] [Abstract][Full Text] [Related]
5. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
Viallard C; Larrivée B
Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
[TBL] [Abstract][Full Text] [Related]
6. Controlling escape from angiogenesis inhibitors.
Sennino B; McDonald DM
Nat Rev Cancer; 2012 Oct; 12(10):699-709. PubMed ID: 23001349
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor vascularization: promising strategies for vascular normalization.
Zheng R; Li F; Li F; Gong A
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2489-2505. PubMed ID: 34148156
[TBL] [Abstract][Full Text] [Related]
8. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Jain RK
Science; 2005 Jan; 307(5706):58-62. PubMed ID: 15637262
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions.
Lin Z; Zhang Q; Luo W
Eur J Pharmacol; 2016 Dec; 793():76-81. PubMed ID: 27840192
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
11. [Immune therapy and tumor angiogenesis].
Takakura N
Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547
[TBL] [Abstract][Full Text] [Related]
12. [A concept of regulating tumor microenvironment immune and normalizing angiogenesis by Chinese medicine drug therapy for supporting zheng-qi to prop up root].
Xiong L; Tian SX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Feb; 30(2):201-4. PubMed ID: 20462053
[TBL] [Abstract][Full Text] [Related]
13. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.
Shang B; Cao Z; Zhou Q
Front Med; 2012 Mar; 6(1):67-78. PubMed ID: 22460450
[TBL] [Abstract][Full Text] [Related]
14. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
15. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
16. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
17. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
Fukumura D; Jain RK
Microvasc Res; 2007; 74(2-3):72-84. PubMed ID: 17560615
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy: Markers of response, "normalization" and resistance.
El Alaoui-Lasmaili K; Faivre B
Crit Rev Oncol Hematol; 2018 Aug; 128():118-129. PubMed ID: 29958627
[TBL] [Abstract][Full Text] [Related]
19. Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Cao Y
Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436
[TBL] [Abstract][Full Text] [Related]
20. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
